Transarterial Chemoembolization Prior to Liver Transplantation in @entity1 with XXXX .

@entity5 @entity1 @entity157 @entity39
BACKGROUND Transarterial chemoembolization (TACE) induces @entity39 , which is intensified by regional chemotherapy. By reducing the active @entity5 tissue, it can be assumed that @entity1 on the waiting list for liver transplantation may benefit from this locoregional treatment. The aim of this study was to assess the relevance of @entity157 ( @entity157 ) @entity1 before liver transplantation. MATERIAL AND METHODS A retrospective analysis was performed on data of 229 @entity1 who were transplanted for @entity157 . A group of 75 @entity1 were treated with TACE prior to liver transplantation. Tumor @entity39 related to pretransplantation locoregional treatment was assessed in an explanted liver and classified into extensive (51-100%), moderate (26-50%) and limited (<25%) grades. Five-year recurrence-free survival was estimated using the Kaplan-Meier method and compared using the log-rank test. RESULTS In total, 143 @entity157 were treated with TACE. Extensive @entity39 was found in 63 (44.0%) @entity5 . Moderate and limited @entity39 were observed in 42 (29.4%) and 38 (26.6%) @entity5 , respectively. In 36 (58.1%) explanted livers, every @entity5 was classified as extensively @entity39 . The 5-year recurrence-free survival was estimated as 81.6% in the group not treated with TACE prior to liver transplantation (TACE-) and as 73.1% in the TACE+ group (p=0.169). Among @entity1 not fulfilling the Milan criteria, 5-year recurrence-free survival was 63.1% in TACE- and 65.1% in TACE+ (p=0.656). CONCLUSIONS In conclusion, TACE prior to liver transplantation is effective in inducing @entity39 . However, evidence of benefits in long-term results after liver transplantation requires further confirmation.
